BG
BOLD

BlackRock Group’s Audentes Therapeutics, Inc BOLD Stock Holding History

BlackRock Group’s Portfolio BOLD Stock Details BOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$1.86M Hold
102,058
– – ﹤0.01% 1817
2016
Q3 		$1.82M Buy
+102,058
New +$1.55M ﹤0.01% 1687

Other funds holding BOLD

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
VMI
VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return

BlackRock Group's BOLD Position: Q4 2016 in Review

BlackRock Group held its Audentes Therapeutics, Inc (BOLD) position steady in Q4 2016 at 102,058 shares worth $1.86M. The position accounts for ﹤0.01% of the portfolio, ranked #1817.

BlackRock Group first reported a position in BOLD in Q3 2016 and has held it in 2 quarters since. 57 funds tracked by Wall St. Rank hold BOLD as of Q4 2016.

  • BlackRock Group held 102,058 shares of Audentes Therapeutics, Inc worth $1.86M as of Q4 2016.
  • BlackRock Group left its Audentes Therapeutics, Inc share count unchanged in Q4 2016.
  • Audentes Therapeutics, Inc made up ﹤0.01% of BlackRock Group's portfolio in Q4 2016, its #1817 holding.
  • BlackRock Group first reported a position in Audentes Therapeutics, Inc in Q3 2016 and has held it in 2 quarters since.
  • 57 funds tracked by Wall St. Rank held Audentes Therapeutics, Inc as of Q4 2016.

Based on BlackRock Group's 13F filing for Q4 2016, filed 10 Feb 2017.